Banque Transatlantique SA Purchases Shares of 4,059 CVS Health Corporation $CVS

Key Points

• Banque Transatlantique SA has made a new investment of approximately $254,000 in CVS Health Corporation, acquiring 4,059 shares during the first quarter.
• CVS Health recently reported quarterly earnings of $1.81 EPS, exceeding analysts' estimates, with revenues of $98.92 billion.
• The company announced a quarterly dividend of $0.665 per share, representing a yield of 3.6%.

Banque Transatlantique SA bought a new stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,059 shares of the pharmacy operator's stock, valued at approximately $254,000.

Other large investors have also recently modified their holdings of the company. Cary Street Partners Financial LLC bought a new position in CVS Health in the 4th quarter valued at $647,000. Brevan Howard Capital Management LP bought a new position in CVS Health in the 4th quarter valued at $1,134,000. Cetera Investment Advisers grew its position in CVS Health by 2.1% in the 4th quarter. Cetera Investment Advisers now owns 318,779 shares of the pharmacy operator's stock valued at $14,310,000 after acquiring an additional 6,524 shares during the last quarter. CoreCap Advisors LLC grew its position in CVS Health by 18.6% in the 4th quarter. CoreCap Advisors LLC now owns 4,328 shares of the pharmacy operator's stock valued at $194,000 after acquiring an additional 679 shares during the last quarter. Finally, Dimension Capital Management LLC bought a new position in CVS Health in the 4th quarter valued at $342,000. Institutional investors own 80.66% of the company's stock.

CVS Health Stock Up 0.1%

Shares of NYSE CVS traded up $0.07 during mid-day trading on Friday, reaching $73.76. 5,074,859 shares of the company were exchanged, compared to its average volume of 5,735,610. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. The stock has a market cap of $93.56 billion, a price-to-earnings ratio of 20.60, a P/E/G ratio of 0.81 and a beta of 0.62. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $74.53. The firm has a 50-day moving average of $66.60 and a 200 day moving average of $65.99.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.35. The firm had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.83 EPS. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date was Tuesday, July 22nd. CVS Health's dividend payout ratio is 74.30%.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.22% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CVS has been the topic of several research analyst reports. Barclays upped their price objective on CVS Health from $80.00 to $87.00 and gave the company an "overweight" rating in a research report on Thursday. UBS Group raised CVS Health from a "neutral" rating to a "buy" rating and increased their price target for the stock from $67.00 to $79.00 in a research report on Monday, August 18th. Truist Financial increased their price target on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Cantor Fitzgerald reissued an "overweight" rating and set a $78.00 price target on shares of CVS Health in a research report on Tuesday, August 26th. Finally, Bernstein Bank dropped their price target on CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CVS Health currently has a consensus rating of "Buy" and a consensus target price of $77.89.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.